# Wall Street's Wildest Stock Picks: October 2026

Newsy: Bud Fox's 3 Controversial Stocks of the Day
Published: 2026-10-03T23:40:01.825Z
Source: https://newsyai.com/edition/24a17894-bf4a-47c3-97ed-3d612d631366
Archive: https://newsyai.com/newsy/bde0e0f6-7fac-4abb-93a8-996b5464e3e9.md

---

**Wall Street's Fresh Holy Trinity of "WTF Is This Stock Smoking?" – October 3, 2026 Edition**[[1]](https://www.findmymoat.com/short-interest)

Back at it, you beautiful degenerates. Markets are still a glorious shitshow—AI hype juicing the Nasdaq while the Dow sits there like a bored hooker and crude oil bounces around like a meth-fueled pinball. I scoured the latest short-interest data (Sep 15/25 settlement vibes dominating, with fresh scans) for three *brand-new* names where the bears are piled on like it's a clearance sale on doom, and the bulls are yelling "squeeze this, motherfucker." No repeats of the usual suspects like XPOF/KPTI/PCT/RXRX/NEGG/CLSK/HTZ/PLCE/etc.—just fresh chaos with shorts north of 35% (or damn close in the scans) screaming "prove me wrong, bitch." Here's the latest holy trinity of pure, unfiltered "who the fuck knows?"

### 1. VG (Venture Global): The LNG Export Empire Hustle
**The Bull Case (We're the Kings of Liquefied Natural Gas—Modular Magic and Contract Cash to the Moon):**  
Bulls are hyped on VG's rapid ramp in U.S. LNG exports, modular construction for fast scaling to massive capacity (70+ MTPA by 2028 vibes), long-term contracts locking in revenue, and tailwinds from global energy demand, Europe's security needs, and AI data center power hunger. Shorts are stacked heavy (~80% float in some aggressive scans), but any production milestones, new offtake deals, or "finally monetizing the boom" narrative could trigger a violent short squeeze. "We've got the assets and the contracts—watch the cargoes flow and shorts get liquefied" is the cope. Expansion? Margin leverage? Shorts left choking on the fumes.[[2]](https://seekingalpha.com/article/4923767-venture-global-full-lng-steam-ahead)

**The Bear Case (Litigation Nightmare and Earnings Cliff in a Debt-Laden Jungle):**  
Reality check: High debt load, ongoing litigation risks (BP/Shell arbitration drama), an impending earnings drop post-COD as high-margin pre-commercial sales end, execution risks on expansions, and macro sensitivity to LNG prices or recessions. High shorts reflect the market's "yeah, right" on sustainable profitability and balance sheet health. One bad ruling, delay, or price slump and it's dilution or worse. Venture Global? More like "venture into value destruction."[[3]](https://seekingalpha.com/article/4858778-venture-global-far-too-expensive-after-the-cod-pay-cut)

**My First-Principles Breakdown:**  
Strip it down: LNG export wins on cheap U.S. feedstock, scalable infrastructure, contracted cash flows, and global supply/demand—not just hype. VG has the modular edge and growth runway, but "scaling to dominance" assumes surviving legal overhang, debt servicing, and commodity cycles where spot prices can crater. Shorts correctly price in the binary risks and leverage; bulls correctly price in the asymmetric upside if energy demand stays hot. High-vol energy lottery ticket—entertaining as hell, size accordingly or cry into your fuel bill later.

### 2. BROS (Dutch Bros): The Drive-Thru Coffee Cult
**The Bull Case (We're the Next Big Thing in Caffeine—Unit Growth and Brand Mojo to the Moon):**  
Bulls are pumped on Dutch Bros' drive-thru-only model, rapid store expansion (hundreds of new openings), same-store sales beats, recurring customer obsession, and tailwinds from coffee culture and convenience. Shorts are aggressive (~40% of float in recent data), but any earnings beats, new market entries, or "people still crave that quirky energy drink coffee" narrative could spark a squeeze. "We've got the cult following and the unit economics—watch the royalties (or comps) roll and shorts get java-jacked" is the mantra. Margin expansion? Loyalty program traction? Shorts left wired and wired wrong.[[4]](https://www.quiverquant.com/news/Dutch+Bros+Inc+Stock+Short+Interest+Rises+to+41.53%25)

**The Bear Case (Overhyped Valuation in a Crowded Caffeine Graveyard):**  
Reality bites: Sky-high multiples pricing in perfection, rising capex and lease liabilities, competition from bigger chains and independents, macro headwinds on discretionary spend, potential GLP-1 weight-loss drug impacts on cravings, and decelerating growth signals. High shorts aren't random—they're the market saying "this execution story is stretched." One missed comp, slowdown, or economic wobble and it's multiple compression city or worse. Dutch Bros? More like "Dutch bros, your portfolio's toast."[[5]](https://seekingalpha.com/article/4950352-a-pair-trade-in-the-coffee-space-short-dutch-bros-and-go-long-coffee-holding)

**My First-Principles Breakdown:**  
Fundamentally, drive-thru beverage wins on convenience, brand differentiation, scalable real estate-light model, and consumer habit—not just hype. BROS has the quirky moat and growth runway, but "compounding forever" assumes surviving competition, cost inflation, and cycles where people cut back on premium coffee first. Shorts correctly flag the valuation and cyclical risks; bulls correctly flag the asymmetric upside if the cult stays caffeinated. High-vol retail bet—entertaining as hell, size accordingly or cry into your oat milk latte later.

### 3. BEAM (Beam Therapeutics): The Gene-Editing Moonshot
**The Bull Case (We're Cracking the Genetic Code—Pipeline Catalysts and Platform Power Incoming):**  
Bulls hype BEAM's base-editing tech for precise gene fixes, promising pipeline in sickle cell, AATD, and beyond, potential partnerships or buyout vibes, and "niche but sticky" positioning in next-gen editing. Shorts are piled on (~25-35% of float), but any positive trial data, BLA progress, or "finally differentiating from CRISPR" news could spark a squeeze. "We've got the science edge and the unmet need—watch the approvals flow and shorts get edited out" is the rally cry. Data readouts? Commercial traction? Shorts left in the dust.[[6]](https://seekingalpha.com/article/4917997-beam-therapeutics-better-entry-point-likely-coming)

**The Bear Case (Cash-Burning Biotech with Competition Breathing Down Its Neck):**  
Reality bites: Ongoing cash burn and dilution risk to fund trials, intense competition from bigger players and rival editing tech, long/uncertain timelines to meaningful revenue, and a valuation that bakes in success. High shorts reflect the market's "yeah, right" on execution in a binary, high-failure field. One failed trial, regulatory setback, or funding crunch and it's back to square one or worse. Beam? More like "beam me up, Scotty—out of this stock."[[7]](https://www.marketbeat.com/stocks/NASDAQ/BEAM/short-interest/)

**My First-Principles Breakdown:**  
Oncology/gene-editing biotech lives or dies on probability of success, capital efficiency, differentiation, and regulatory paths—not just early promise. BEAM has a differentiated platform and pipeline optionality, but "growth" requires surviving deeper-pocketed rivals and proving durable clinical/commercial value. Shorts flag the binary technical/financial risks; bulls flag the asymmetric upside if data clicks. High-risk biotech bet with squeeze lottery potential—trade the catalysts, not your retirement.

**Bottom Line (No Crystal Ball, Just Brutal Logic):**  
These three capture the current divided vibe: LNG infrastructure bet, coffee chain growth gamble, and gene-editing biotech moonshot. The common thread? Sky-high skepticism via shorts, but real catalysts that could flip the script. Markets adore punishing uncertainty—and these names are marinated in it. Laugh at the chaos, size positions like your rent depends on it (or don't), and remember: this is entertainment with numbers. Your move, degenerates.

**Sources for the terminally curious (verify this shit yourself):** Recent short-interest trackers and screens (e.g., FindMyMoat, Tapeboard, Benzinga, MarketBeat, Seeking Alpha) highlighting elevated levels in VG, BROS, and BEAM; market commentary on the underlying sector debates. Always do your own digging—these are snapshots of a deranged market. Trade responsibly, or at least don't cry when it goes tits up.
